The global warm autoimmune hemolytic anemia (WAIHA) treatment market garnered a market value of USD 582.99 Million in 2022 and is expected to accumulate a market value of USD 1598 Million by registering a CAGR of 9.6% in the forecast period 2023 to 2033.
Growth of the autoimmune hemolytic anemia (WAIHA) treatment market can be attributed to increasing prevalence of WAIHA, rising awareness and diagnosis rates, and the development of new and effective treatment options. The market for autoimmune hemolytic anemia (WAIHA) treatment registered a CAGR of 5.4% in the historical period 2018 to 2022
Warm autoimmune hemolytic anemia (WAIHA) treatment refers to the medical interventions used to manage the symptoms and underlying causes of WAIHA. WAIHA is an autoimmune disorder in which the immune system mistakenly attacks and destroys red blood cells, leading to anemia.
The treatment of WAIHA usually involves the use of immunosuppressive drugs, such as corticosteroids, to suppress the immune system and reduce the destruction of red blood cells. Other treatments may include immunomodulatory drugs, such as rituximab or cyclophosphamide, which target specific components of the immune system to reduce the autoimmune response.
In some cases, blood transfusions may be used to replace the destroyed red blood cells and improve symptoms. In severe cases, a splenectomy (surgical removal of the spleen) may be necessary to reduce the destruction of red blood cells.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | USD 638.96 Million |
| Anticipated Forecast Value (2033) | USD 1598 Million |
| Projected Growth Rate (2023 to 2033) | 9.6% CAGR |
Explore FMI!
Book a free demo
According to market research and competitive intelligence provider Future Market Insights- the market for Autoimmune hemolytic anemia (WAIHA) treatment reflected a value of 5.4% during the historical period, 2018 to 2022.
The pharmaceutical industry has seen a growing interest in the development of new treatments for autoimmune diseases, including AIHA. Some companies have been working on developing novel therapies that target specific immune system pathways and molecules involved in the development of autoimmune diseases.
In recent years, several new drugs have been approved by regulatory agencies for the treatment of autoimmune diseases, including AIHA. For example, in 2019, the USA Food and Drug Administration (FDA) approved a new drug called zilucoplan (brand name: Viltepso) for the treatment of autoimmune hemolytic anemia.
Overall, the market for autoimmune disease treatments is expected to continue growing in the coming years, driven by factors such as increasing prevalence of autoimmune diseases and a growing demand for more effective and targeted therapies. Thus, the market for Autoimmune hemolytic anemia (WAIHA) treatment is expected to register a CAGR of 9.6% in the forecast period 2023 to 2033.
Increasing prevalence of autoimmune diseases and advancements in medical technology driving market growth
The prevalence of autoimmune diseases such as WAIHA has been on the rise globally, which has led to a growing demand for effective treatment options. Advancements in medical technology have enabled the development of new diagnostic tools and treatment options for WAIHA.
For example, the introduction of advanced imaging techniques has made it easier to diagnose WAIHA and monitor the progression of the disease.
The trend towards personalized medicine has led to a greater emphasis on developing targeted therapies for specific diseases, including WAIHA. Governments and pharmaceutical companies are investing heavily in research and development to discover new therapies for WAIHA. This has led to the development of novel drugs and treatments that are more effective and have fewer side effects.
The increasing healthcare expenditure by governments and individuals has contributed to the growth of the WAIHA treatment market. As more resources are allocated to healthcare, patients are able to access better treatment options for WAIHA.
Treatments available for WAIHA shaping landscape for growth of market
Corticosteroids: Corticosteroids such as prednisone are often the first-line treatment for WAIHA. These drugs suppress the immune system and reduce the destruction of red blood cells.
Immunomodulatory drugs: Immunomodulatory drugs such as rituximab, azathioprine, and cyclophosphamide are used in cases where corticosteroids are not effective or cause significant side effects. These drugs also work to suppress the immune system and reduce the destruction of red blood cells.
Blood transfusions: In severe cases of WAIHA, blood transfusions may be necessary to replace the lost red blood cells.
Splenectomy: In some cases, removal of the spleen (splenectomy) may be necessary to reduce the destruction of red blood cells. This is because the spleen is the primary site of red blood cell destruction in WAIHA.
Immunoglobulin therapy: Immunoglobulin therapy involves the infusion of immunoglobulin proteins that can help to reduce the destruction of red blood cells by the immune system.
Other treatments: Other treatments for WAIHA may include plasma exchange, phototherapy, and chemotherapy.
Lack of specific diagnostic tests and limited understanding of the disease derailing market growth
There is currently no single diagnostic test that can confirm a diagnosis of WAIHA. The diagnosis is often made through a combination of clinical evaluation, laboratory tests, and imaging studies, which can lead to delays in diagnosis and treatment.
Despite advances in medical research, the exact causes of WAIHA are not yet fully understood. This limited understanding makes it difficult to develop targeted treatments for the disease. There are currently limited treatment options available for WAIHA, and existing treatments such as corticosteroids can have significant side effects. This can make it challenging for patients to find effective treatment options.
The cost of treating WAIHA can be high, especially for patients who require long-term therapy. This can make it difficult for some patients to access the treatment they need. Treatment for WAIHA often involves a combination of drugs and therapies that need to be taken over a long period of time. This can be challenging for some patients, and may impact the effectiveness of the treatment.
Advanced healthcare infrastructure bolstering market growth of WAIHA market in North America
The United States has a high prevalence of autoimmune diseases, which has contributed to the growth of the WAIHA treatment market in North America. The North American region has advanced healthcare infrastructure and a highly skilled workforce, which has enabled the development of new diagnostic tools and treatment options for WAIHA.
The United States is a major contributor to research and development in the healthcare industry. The country invests heavily in research and development of new therapies for autoimmune diseases, including WAIHA. The trend towards personalized medicine has led to a greater emphasis on developing targeted therapies for specific diseases, including WAIHA.
The high healthcare expenditure in North America has contributed to the growth of the WAIHA treatment market. Patients are able to access better treatment options for WAIHA due to the availability of resources. Thus, North America is expected to possess 46% market share for WAIHA treatment market in 2023.
Demand for personalized medicines creating lucrative opportunities for WAIHA market in Europe
The prevalence of autoimmune diseases is on the rise, including WAIHA, which is driving the demand for effective treatment options. Advances in healthcare technology are leading to the development of new diagnostic tools and treatment options for WAIHA, which are more effective and have fewer side effects.
The trend towards personalized medicine is driving the development of targeted therapies for specific diseases, including WAIHA. Rising healthcare expenditure globally is increasing the availability of resources for the development and commercialization of new treatments for WAIHA.
The strong pipeline of drugs in development for the treatment of WAIHA is expected to contribute to the growth of the market in the coming years. Awareness and education: Greater awareness and education about autoimmune diseases, including WAIHA, is leading to earlier diagnosis and treatment, which is expected to drive the growth of the market. Thus, Europe is expected to possess 41% market share for WAIHA treatment market in 2023.
Accessibility to experts favoring growth of hospital pharmacies for WAIHA treatment market
Hospital pharmacists have specialized training and experience in managing complex medical conditions and administering medications to patients. They work closely with healthcare providers to ensure that patients receive the appropriate medication at the right dosage and frequency.
Hospital pharmacies often have a wider range of medications available for use in treating WAIHA, including newer and more advanced therapies that may not be available at other pharmacies. Hospital pharmacies are subject to rigorous quality control standards and regulations, which ensures the safety and efficacy of medications dispensed to patients.
Hospital pharmacists work collaboratively with other healthcare providers, including physicians and nurses, to ensure that patients receive comprehensive and coordinated care. Hospital pharmacists have access to the patient's medical records and can monitor medication use and potential side effects closely.
This ensures that patients receive the most appropriate treatment and that any potential issues are addressed promptly. Thus, hospital pharmacies are expected to hold 45% market share for WAIHA treatment market in 2023.
Key players in the warm autoimmune hemolytic anemia (WAIHA) treatment market are Rigel Pharmaceuticals, Apellis Pharmaceuticals, Inc., Sanofi, Incyte Corporation, Teva Pharmaceutical Industries Ltd, Momenta Pharmaceuticals, Alexion Pharmaceuticals, Inc., Immunovant, F. Hoffmann-La Roche Ltd
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | USD 638.96 Million |
| Market Value in 2033 | USD 1598 Million |
| Growth Rate | CAGR of 9.6% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2018 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segments Covered | Drug Class, Distribution Channel, Region |
| Regions Covered | North America; Latin America; Europe; South Asia; East Asia; Oceania; Middle East & Africa |
| Key Countries Profiled | USA, Canada, Brazil, Mexico, Rest of Latin America, Germany, United kingdom, France, Spain, Italy, Rest of Europe, India, Malaysia, Singapore, Thailand, Rest of South Asia, China, Japan, South Korea, Austria, New Zealand, GCC countries, South Africa, Israel, Rest of MEA |
| Key Companies Profiled | Rigel Pharmaceuticals; Apellis Pharmaceuticals, Inc.; Sanofi; Incyte Corporation; Teva Pharmaceutical Industries Ltd; Momenta Pharmaceuticals; Alexion Pharmaceuticals, Inc.; Immunovant; F. Hoffmann-La Roche Ltd |
| Customization | Available Upon Request |
North America is projected to emerge as a lucrative market.
The growth potential of the market is 9.6% through 2033.
The high cost of adoption is likely to limit market growth.
North America is likely to secure a share of 46% in 2023.
The market is estimated to secure a valuation of USD 582.99 million in 2023.
Home Respiratory Therapy Market – Growth & Forecast 2025 to 2035
Veterinary Auto-Immune Therapeutics Market Growth - Trends & Forecast 2025 to 2035
Radial Compression Devices Market Growth - Trends & Forecast 2025 to 2035
Digital Telepathology Market is segmented by Application and End User from 2025 to 2035
Suture Anchor Devices Market Is Segmented by Product Type, Material Type, Tying and End User from 2025 to 2035
Home Infusion Therapy Devices Market - Growth & Forecast 2025 to 2035
Warm Autoimmune Hemolytic Anemia (WAIHA) Treatment Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
